Roth Capital Predicts Higher Earnings for Zevra Therapeutics

Key Points

• Roth Capital has raised its Q3 2025 earnings per share forecast for Zevra Therapeutics from ($0.04) to ($0.03), while the consensus estimate for the full year remains at ($1.95) per share.
• Zevra Therapeutics reported Q2 earnings of ($0.06) per share, missing expectations significantly, although revenue exceeded estimates at $25.88 million.
• Several analysts have issued updated ratings and price targets for Zevra Therapeutics, with a consensus price target of $23.71, reflecting a generally positive outlook on its stock.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Roth Capital boosted their Q3 2025 earnings per share (EPS) estimates for Zevra Therapeutics in a research note issued on Wednesday, August 13th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.03) per share for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics' Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.86 EPS, FY2027 earnings at $1.63 EPS, FY2028 earnings at $2.05 EPS and FY2029 earnings at $2.48 EPS.

Several other equities research analysts have also recently issued reports on ZVRA. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Wall Street Zen cut Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 20th. Zacks Research downgraded Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday. HC Wainwright assumed coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Finally, Cantor Fitzgerald raised their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $23.71.

Zevra Therapeutics Stock Up 3.0%

NASDAQ ZVRA traded up $0.27 on Friday, hitting $9.28. 430,788 shares of the stock were exchanged, compared to its average volume of 732,120. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The company has a market cap of $520.93 million, a PE ratio of -44.19 and a beta of 1.87. The company has a 50-day moving average price of $10.55 and a 200-day moving average price of $8.78.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. grew its stake in shares of Zevra Therapeutics by 30.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company's stock valued at $49,000 after purchasing an additional 1,280 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company's stock worth $179,000 after purchasing an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after buying an additional 1,812 shares during the last quarter. Invesco Ltd. grew its position in Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after buying an additional 3,007 shares during the last quarter. Finally, Carret Asset Management LLC increased its stake in Zevra Therapeutics by 9.7% in the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company's stock valued at $349,000 after buying an additional 3,500 shares during the period. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.